Nigericin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Nigericin
Accession Number
DB14056
Type
Small Molecule
Groups
Experimental
Description

A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed)

Structure
Thumb
Synonyms
  • Azalomycin M
  • Helixin C
  • Polyetherin A
External IDs
Antibiotic K 178 / Antibiotic X-464 / BRN 1696755 / X-464
Product Ingredients
IngredientUNIICASInChI Key
Nigericin sodiumDGN38HI97628643-80-3MOYOTUKECQMGHE-PDEFJWSRSA-M
Categories
UNII
RRU6GY95IS
CAS number
28380-24-7
Weight
Average: 724.973
Monoisotopic: 724.47616301
Chemical Formula
C40H68O11
InChI Key
DANUORFCFTYTSZ-SJSJOXFOSA-N
InChI
InChI=1S/C40H68O11/c1-21-11-12-28(46-33(21)26(6)36(42)43)17-29-18-30(45-10)27(7)40(48-29)25(5)19-38(9,51-40)32-13-14-37(8,49-32)35-23(3)16-31(47-35)34-22(2)15-24(4)39(44,20-41)50-34/h21-35,41,44H,11-20H2,1-10H3,(H,42,43)/t21-,22-,23-,24+,25+,26+,27+,28+,29+,30+,31+,32+,33+,34-,35+,37-,38-,39-,40+/m0/s1
IUPAC Name
(2R)-2-[(2R,3S,6R)-6-{[(2S,4R,5R,7R,9R,10R)-2-[(2S,2'R,3'S,5R,5'R)-5'-[(2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-2,3'-dimethyl-[2,2'-bioxolan]-5-yl]-9-methoxy-2,4,10-trimethyl-1,6-dioxaspiro[4.5]decan-7-yl]methyl}-3-methyloxan-2-yl]propanoic acid
SMILES
[H][C@@]1(C[C@H](C)[C@@]([H])(O1)[C@]1(C)CC[C@@]([H])(O1)[C@]1(C)C[C@@H](C)[C@]2(O1)O[C@]([H])(C[C@@]1([H])CC[C@H](C)[C@@]([H])(O1)[C@@H](C)C(O)=O)C[C@@H](OC)[C@H]2C)[C@@]1([H])O[C@@](O)(CO)[C@H](C)C[C@@H]1C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Nigericin is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Nigericin is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Nigericin is combined with 4-hydroxycoumarin.
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Nigericin.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Nigericin.
AcenocoumarolThe risk or severity of bleeding can be increased when Nigericin is combined with Acenocoumarol.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Nigericin.
AcetyldigoxinNigericin may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Nigericin.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nigericin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Steinrauf LK, Pinkerton M, Chamberlin JW: The structure of nigericin. Biochem Biophys Res Commun. 1968 Oct 10;33(1):29-31. [PubMed:5696503]
External Links
KEGG Compound
C11609
ChemSpider
10196461
ChEBI
7569
ChEMBL
CHEMBL405862
Wikipedia
Nigericin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00137 mg/mLALOGPS
logP4.09ALOGPS
logP6.11ChemAxon
logS-5.7ALOGPS
pKa (Strongest Acidic)4.07ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area142.37 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity189.1 m3·mol-1ChemAxon
Polarizability81.84 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on June 12, 2018 14:54 / Updated on November 02, 2019 04:43